Adenocarcinoma Clinical Trials

Birmingham : Birmingham Hematology and Oncology Associates, LLC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Birmingham : Birmingham Hematology and Oncology Associates, LLC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Birmingham :

Study of Ruxolitinib in Pancreatic Cancer Patients

Mobile : University of South Alabama Mitchell Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Chandler : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Gilbert : Banner Healthcare

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Glendale : Arizona Center for Cancer Care

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Mesa : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Scottsdale : TGen Clinical Research Service at Scottsdale Healthcare

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

View More »

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Scottsdale : Scottsdale Healthcare

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Scottsdale : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

Scottsdale :

AMG 172 First in Human Study in Patients With Kidney Cancer

Hot Springs :

Study of Ruxolitinib in Pancreatic Cancer Patients

Alhambra : Central Hematology Oncology Medical Group, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Alhambra : Central Hematology Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Anaheim : Pacific Cancer Medical Center, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Bakersfield : Comprehensive Blood and Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Bakersfield : Comprehensive Blood and Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

View More »

Burbank :

Study of Ruxolitinib in Pancreatic Cancer Patients

Corona : Wilshire Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Duarte : City of Hope Cancer Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Fountain Valley : Compassionate Cancer Care Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Fresno : California Cancer Associates for Research and Excellence (CCARE)

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Fullerton : Saint Jude Heritage Healthcare

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Glendale : White Memorial Medical Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

La Jolla : UCSD Moores Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Long Beach : Pacific Shores Medical Group

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Long Beach : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Long Beach : Pacific Shores Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Los Angeles : UCLA Community Oncology Practice

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Los Angeles : Comprehensive Hematology Oncology Centers, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Los Angeles : UCLA Community Oncology Practice

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Los Angeles : Cedars Sinai Medical Center SC

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Los Angeles :

Study of Ruxolitinib in Pancreatic Cancer Patients

Oakland : Hematology Oncology Associates

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Oceanside : North County Oncology Medical Clinical Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Orange : Hematology Oncology Medical Group of Orange County, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Orange : Hematology Oncology Medical Group of Orange County

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Palm Springs : Desert Comprehensive Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Palo Alto : Stanford University Medical Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Palo Alto : Stanford University Medical Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Pomona : Wilshire Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Rancho Cucamonga : Wilshire Oncology Medical Group, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Redondo Beach : Pacific Shores Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Redondo Beach : Cancer Care Associates Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Sacramento : University of California Davis Cancer Center

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

Salinas : Pacific Cancer Care

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

San Diego : Sharp Health Care

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

San Diego : Sharp Health Care

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

San Francisco : California Pacific Medical Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

San Jose : San Jose Medical Group

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

San Jose : San Jose Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Santa Maria : Central Coast Medical Oncology Corp

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Santa Monica :

Study of Ruxolitinib in Pancreatic Cancer Patients

Stanford : Stanford Cancer Center - Stanford University

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Aurora : University of Colorado Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Aurora : University of Colorado at Denver and Health Science Center

Trial of Preoperative Capecitabine Oxaliplatin Cetuximab & Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma

Denver : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Denver : Kaiser Permanente Colorado

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Denver :

Study of Ruxolitinib in Pancreatic Cancer Patients

View More »

Fort Collins : Poudre Valley Cancer Center of the Rockies

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Grand Junction : Saint Mary's Regional Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Grand Junction : Saint Mary's Regional Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

New Haven : Yale Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Stamford : Hematology Oncology Associates, PC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Stamford : Hematology Oncology Associates, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Stamford : The Stamford Hospital

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Stamford :

Study of Ruxolitinib in Pancreatic Cancer Patients

Newark : Christiana Care Health Services Helen Graham Cancer Center

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Washington : Research Site

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Washington : Georgetown University

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Boynton Beach :

Study of Ruxolitinib in Pancreatic Cancer Patients

Ft. Myers :

Study of Ruxolitinib in Pancreatic Cancer Patients

Gainesville : Florida Cancer Specialists

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Jacksonville : Mayo Clinic Jacksonville

Pancreatic Juice Diagnosis From Duodenum

Jacksonville : Mayo Clinic Florida Updated

Spectroscopy From Duodenum

View More »

Miami Beach : Mount Sinai Comprehensive Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Orlando : Florida Hospital Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Pembroke Pines : Memorial Cancer Institute

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

St. Petersburg : Florida Cancer Specialists

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

St. Petersburg :

Study of Ruxolitinib in Pancreatic Cancer Patients

Tampa : Florida Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Tampa : H. Lee Moffitt Cancer Center/University of South Florida Moffitt 4

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Savannah : Memorial University Medical Center

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

View More »

Atlanta : Georgia Cancer Specialists, P.C.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Atlanta : Peachtree Hematology Oncology Consultants, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Atlanta : Emory University

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Atlanta : Piedmont Hospital Research Institute

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Augusta : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Lawrenceville : Suburban Hematology Oncology Associates, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Honolulu : University of Hawaii Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Arllington Heights :

Study of Ruxolitinib in Pancreatic Cancer Patients

Chicago : University of Chicago Comprehensive Cancer Center

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Chicago : Northwestern University

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Chicago : Northwestern University

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Chicago : The University of Chicago Medical Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

View More »

Chicago : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Chicago : University of Chicago Comprehensive Cancer Center

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Elks Grove Village :

Study of Ruxolitinib in Pancreatic Cancer Patients

Highland Park : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Zion : Cancer Treatment Centers of America (CTCA-Midwestern)

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Goshen : Goshen Center for Cancer Care

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Indianapolis : Indiana University Simon Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Indianapolis :

Study of Ruxolitinib in Pancreatic Cancer Patients

Terre Haute : Providence Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Sioux City :

Study of Ruxolitinib in Pancreatic Cancer Patients

Westwood : University of Kansas Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Crestview Hills : Oncology Hematology Care, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Lexington :

Study of Ruxolitinib in Pancreatic Cancer Patients

Louisville : James Graham Brown Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Louisville : Owsley Brown Frazier Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Louisville :

Study of Ruxolitinib in Pancreatic Cancer Patients

Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Gemcitabine in Combination With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Boston : Dana-Farber Cancer Institute

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Boston : Massachusetts General Hospital Mass General 2 Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Boston : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Boston : Massachusetts General Hospital Dept. of Mass General Hospital

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Boston : Dana Farber Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

View More »

Rockland : Please Contact U.S. Medical Information Located in

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Worcester : UMASS Medical School

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Worcester :

Study of Ruxolitinib in Pancreatic Cancer Patients

Ann Arbor :

Study of Ruxolitinib in Pancreatic Cancer Patients

Detroit : Wayne State University/Karmanos Cancer Institute Wayne St

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Detroit : Karmanos Cancer Institute

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Detroit :

Study of Ruxolitinib in Pancreatic Cancer Patients

Grand Rapids : St. Mary's Trinity Healthcare

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

View More »

Grand Rapids :

Study of Ruxolitinib in Pancreatic Cancer Patients

Kalamazoo : West Michigan Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Kalamazoo : West Michigan Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Novi :

Study of Ruxolitinib in Pancreatic Cancer Patients

Southfield : Providence Cancer Center Oncology and Hematology Care Clinic-Eastside Portland

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Minneapolis : Virginia Piper Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Minneapolis : Virginia Piper Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Minneapolis :

Study of Ruxolitinib in Pancreatic Cancer Patients

Rochester : Mayo Clinic

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Woodbury : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Tupelo : Hematology and Oncology Associates at BridgePoint

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Tupelo : Hematology and Oncology Associates at BridgePoint

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Columbia : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Saint Joseph : Saint Joseph Oncology, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Saint Joseph : Saint Joseph Oncology, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Saint Louis : Washington University School of Medicine

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

St Louis : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

View More »

St. Louis :

Study of Ruxolitinib in Pancreatic Cancer Patients

Billings : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Billings : Billings Clinic Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Missoula : Montana Cancer Institute Foundation c/o Montana Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Lincoln : Southeast Nebraska Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Omaha : Nebraska Cancer Specialists, Methodist Estabrook Cancer Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Henderson : Comprehensive Cancer Centers of Nevada

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Henderson : Comprehensive Cancer Centers of Nevada

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Henderson : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Las Vegas : Comprehensive Cancer Centers of Nevada

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Basking Ridge : Memoral Sloan Kettering Cancer Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Voorhees :

Study of Ruxolitinib in Pancreatic Cancer Patients

Albuquerque : New Mexico Cancer Care Alliance

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Albuquerque :

Study of Ruxolitinib in Pancreatic Cancer Patients

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

A Phase 2 Study of REOLYSIN in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

View More »

Buffalo : Roswell Park Cancer Institute

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Jamaica : Queens Cancer Center of Queens Hospital

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Lake Success :

Study of Ruxolitinib in Pancreatic Cancer Patients

New Hyde Park : Long Island Jewish Medical Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

New York : Weill Cornell Medical College Updated

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

New York : Beth Israel Comprehensive Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

New York : Saint Luke's-Roosevelt Hospital Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

New York : Memorial Sloan Kettering Cancer Center

Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

New York : Memorial Sloan Kettering Cancer Center MSKCC - SC

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

New York : Beth Israel Comprehensive Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

New York : New York University Langone Medical Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

New York : Weill Cornell Medical College

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

New York : Memorial Sloan-Kettering Cancer Center 1275 York Avenue

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

New York : Weill Medical College of Cornell University

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Rochester : University of Rochester Medical Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Sleepy Hollow : Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Syracuse : Research Foundation of State University of New York

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Chapel Hill : University of North Carolina Lineberger Comprehensive Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Chapel Hill : UNC - Chapel Hill

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Chapel Hill : University of North Carolina at Chapel Hill

Prevalence of Dysplasia of the Gastric Cardia

Charlotte : Levine Cancer Institute

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Durham : Duke University Medical Center, Comprehensive Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

View More »

Durham : Research Site

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Durham : Duke University Medical Center

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Durham :

Study of Ruxolitinib in Pancreatic Cancer Patients

Greensboro : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Greensboro : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Greensboro : Cone Health Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Hendersonville : Hendersonville Hematology and Oncology at Pardee

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Hickory :

Study of Ruxolitinib in Pancreatic Cancer Patients

High Point : Emerywood Hematology and Oncology

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

High Point : Emerywood Hematology and Oncology

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Raleigh : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Raleigh : Rex Cancer Center UNC Healthcare

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Winston Salem : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Winston Salem : University of Wake Forest Baptist Medical Center

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Bismarck : St. Alexis Medical Center-Mid Dakota Clinic PC

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Blue Ash : Oncology Hematology Care, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Canton :

Study of Ruxolitinib in Pancreatic Cancer Patients

Cincinatti : Oncology Hematology Care, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Cincinnati : University of Cincinnati Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Columbus : The Ohio State University Comprehensive Cancer Center

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

View More »

Columbus : Ohio State University Medical Center

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Dayton :

Study of Ruxolitinib in Pancreatic Cancer Patients

Middletown : Signal Point Clinical Research Center, LLC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Wilmington : Oncology Hematology Care, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Tulsa :

Study of Ruxolitinib in Pancreatic Cancer Patients

Tulsa : Cancer Treatment Centers of America (CTCA-Southwestern)

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Bend :

Study of Ruxolitinib in Pancreatic Cancer Patients

Portland : Kaiser Permanente Northwest Region Oncology Hematology

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Portland : Kaiser Permanente NW

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Portland :

Study of Ruxolitinib in Pancreatic Cancer Patients

Abington : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Camp Hill : PinnacleHealth

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Daville :

Study of Ruxolitinib in Pancreatic Cancer Patients

Harrisburg : PinnacleHealth

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Harrisburg : Pinnacle Health

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

View More »

Philadelphia : Kimmel Cancer Center at Jefferson University

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Philadelphia : Research Site

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Philadelphia : Thomas Jefferson University

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Philadelphia : Fox Chase Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Philadelphia : Cancer Treatment Centers of America (ERMC)

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Pittsburgh : Hillman Cancer Center

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Pittsburgh : University of Pittsburgh Cancer Institute

Phase II Study of Irinotecan and Panitumumab

Pittsburgh : University of Pittsburgh Cancer Institute

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Pittsburgh :

Study of Ruxolitinib in Pancreatic Cancer Patients

Willow Grove : Abington Hematology Oncology Associates, Inc.

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Charleston : Charleston Hematology Oncology Associates, PA

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Charleston : Charleston Hematology Oncology Associates

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Charleston : Medical University of South Carolina

Feasibility and Safety Study in Patients With Metastatic Pancreatic Adenocarcinoma

Charleston : Medical University of South Carolina - Hollings Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Columbia : South Carolina Oncology Associates

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

View More »

Columbia : South Carolina Oncology Associates

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Florence : McLeod Regional Medical Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Greenville : Gynecologic Oncology Research & Development, LLC

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

Greenville : Institute of Translational Oncology Research

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Knoxville : Tennessee Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Knoxville : Center for Biomedical Research

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Knoxville :

Study of Ruxolitinib in Pancreatic Cancer Patients

Nashville : Sarah Cannon Research Institute

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville : Tennessee Oncology, PLLC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

View More »

Nashville : Tennessee Oncology, PLLC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Nashville : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Nashville : Vanderbilt-Ingram Cancer Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Nashville : Tennessee Oncology, PLLC

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Abilene : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Bedford : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Corpus Christi : Coastal Bend Cancer Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Dallas : Texas Oncology - Baylor Sammons Cancer Center

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Dallas : Mary Crowley Cancer Research Centers - Medical City

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

View More »

Dallas : University of Texas Southwestern Medical Center at Dallas

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Dallas : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Dallas : Mary Crowley Cancer Center

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Dallas : Sammons Cancer Center Sammons Cancer Center SC-2

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Dallas : Texas Oncology, P.A. SC

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Fort Worth : Center for Cancer and Blood Disorders, PC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Fort Worth : Center for Cancer and Blood Disorders, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Garland : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Houston : MD Anderson Cancer Center/University of Texas MD Anderson 2

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Houston : UT MD Anderson Cancer Center

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Houston : UT MD Anderson Cancer Center

Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Houston : UT MD Anderson Cancer Center

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Houston : The University of Texas M. D. Anderson Cancer Center Updated

Spectroscopy From Duodenum

Lubbock : Joe Arrington Cancer Research and Treatment Center

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Lubbock : Joe Arrington Cancer Research and Treatment Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Plano : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

San Antonio : University of Texas Health Science Center at San Antonio

A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

San Antonio : Novartis Investigative Site

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

San Antonio : South Texas Oncology and Hematology, PA

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

San Antonio :

Study of Ruxolitinib in Pancreatic Cancer Patients

Tyler : Texas Oncology - Tyler

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Weatherford : The Center for Cancer and Blood Disorders

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Murray : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Salt Lake City : Utah Cancer Specialists

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Salt Lake City : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman UT

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

View More »

Salt Lake City : Utah Cancer Specialists

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Charlottesville : University of Virginia Health System

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Fairfax : Virginia Cancer Specialists, PC

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Midlothian : Virginia Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Norfolk : VA Oncology Associates

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Norfolk : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

View More »

Richmond : Virginia Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Richmond : Virginia Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Richmond : Virginia Piper Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Richmond :

Study of Ruxolitinib in Pancreatic Cancer Patients

Roanoke : Carilion GYN Oncology Associates

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

Winchester : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Woodbridge : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Seattle : Seattle Cancer Care Alliance / University of Washington

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Seattle : Virginia Mason Medical Center

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Seattle : Virginia Piper Cancer Institute

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Seattle : Seattle Cancer Care Alliance

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Seattle : Swedish Medical Center Cancer Institute

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

View More »

Tacoma : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Green Bay :

Study of Ruxolitinib in Pancreatic Cancer Patients

Madison : University of Wisconsin Comprehensive Cancer Center

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Milwaukee : Medical College of Wisconsin

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Ciudad Autonoma de Buenos Aires : Instituto de Oncologia Angel H. Roffo

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Box Hill : 1200.123.6104 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Camperdown : 1200.123.6101 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Chermside : 1200.123.6102 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Douglas : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Elizabeth Vale : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

View More »

Heidelberg : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Heidelberg : 1200.123.6105 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Kogarah : 1200.123.6107 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Kurralta Park : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Nedlands : 1200.123.6106 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Parkville : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Randwick : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Linz : AKh Linz

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Linz : KH Elisabethinen Linz

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Salzburg : Universitätsklinik für Innere Medizin III

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Wels : Klinikum Kreuzschwestern Wels GmbH

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Zams : St. Vinzenz Krankenhaus Betriebs GmbH

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Brussels : Novartis Investigative Site

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Brussels (anderlecht) : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Brussels (woluwe-st-lambert) : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Bruxelles : Hôpital Erasme Updated

Spectroscopy From Duodenum

Gent : Novartis Investigative Site

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

View More »

Jette : AZ VUB

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Leuven : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Leuven : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Liege : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Wilrijk : Novartis Investigative Site

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Sofia : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Brampton : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Edmonton : Cross Cancer Institute

First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.

Edmonton : 1200.123.1005 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Edmonton : Novartis Investigative Site

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Fredericton : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Halifax : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Laval : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Montreal : Jewish General Hospital

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Montreal : Montreal General Hospital

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Montreal : 1200.123.1001 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Montreal : 1200.123.1007 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Oshawa : 1200.123.1006 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Ottawa : 1200.123.1003 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Rimouski : GSK Investigational Site

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Surrey : 1200.123.1004 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Toronto : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Toronto : Princess Margaret Hospital

Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

Vancouver : 1200.123.1002 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Beijing : Chinese People's Liberation Army (PLA) General Hospital

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Beijing : Department of GI Oncology, Peking University, School of Oncology

Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Changchun : The First Bethune Hospital of Jilin Univercity

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Chengdu : Sichuan Provincal Tumor Hospital

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Harbin : Harbin Medical Univercity Cancer Hospital

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

View More »

Shenyang : The First Hospital of China Medical University

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Shijiazhuang : Hebei Provincal Tumor Hospital

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Xian : Xijing Hospital

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Zhengzhou : Henan Provincal Tumor Hospital

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Brno : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Olomouc : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Praha 2 : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Bayonne : 1200.123.3307 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Caen Cedex 05 : 1200.123.3305 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Créteil Cedex : 1200.123.3303 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

La Tronche : 1200.123.3309 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Limoges Cedex : 1200.123.3308 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

View More »

Lyon Cedex 08 : 1200.123.3301 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Saint Herblain Cedex : 1200.123.3302 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Saint-Pierre Cedex -La Réunion : 1200.123.3306 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Toulouse Cedex 3 : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Villejuif : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

Villejuif : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Berlin : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Bielefeld : Onkologische Schwerpunktpraxis Bielefeld

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) CLDN18.2-positive Gastric Cancer

Bielefeld : Onkologische Schwerpunktpraxis Bielefeld

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Brandenburg : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Braunschweig : Prof. Dr. F. Lordick

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

View More »

Chemnitz : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Cottbus : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Darmstadt, Germany : Please contact Merck KGaA Communication Center located in

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

Dresden : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Elstra : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Essen : Universitätsklinikum Essen, Innere Klinik Tumorforschung

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) CLDN18.2-positive Gastric Cancer

Essen : 1200.123.4901 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Essen : Novartis Investigative Site

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Esslingen : 1200.123.4905 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Freiburg : University Hospital Freiburg Gynecological Clinic

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Freital : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Fürstenwalde : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Halle/Saale : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Halle/Saale : Universitätsklinikum Halle/Saale; Poliklinik für innere Medizin iV

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) CLDN18.2-positive Gastric Cancer

Hamburg : University Hospital Hamburg-Eppendorf

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Heidelberg : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

Kassel : Hospital Kassel

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Köthen : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Kronach : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Leipzig : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Leipzig : Hospital

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Magdeburg : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Mainz : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Mainz : 1200.123.4902 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Mannheim : Tagestherapiezentrum am ITM & III. Medizinische Klinik Universitätsmedizin Mannheim

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Meiningen : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Mühlhausen : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Münster : 1200.123.4903 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Parchim : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Plauen : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Scheibenberg : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Torgau : Clinic

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Werdau : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Würzburg : University Hospital Würzburg

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Zittau : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Zwickau : Practice

A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Budapest :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Budapest : Semmelweis University, 3rd Department of Internal Medicine

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Budapest : Semmelweis University Department of Diagnostic Radiology and Oncotherapy

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Budapest : Semmelweis University; Clinic for Pulmonology

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Debrecen : University of Debrecen Medical and Health Science Center, Clinic of Pulmonology

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

View More »

Deszk :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Deszk : Hospital for Thoracic Diseases of Csongrad County Local Government

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Mátraháza :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Pecs :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Szekesfehervar :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Szolnok : Hetenyi Geza Hospital 5004, Szolnok, Hungary

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Törökbálint :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Bangalore : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Chennai : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Hyderabad : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Nagpur : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Pune : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Vellore : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Dubliin 9 : 1200.123.3532 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Dublin 8 : 1200.123.3531 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Haifa : Rambam medical Center

Immunochemotherapy for Metastatic Renal Cell Carcinoma

Ancona : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Milano : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Milano : Novartis Investigative Site

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Napoli : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Pisa : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Pisa : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Roma : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Rome : Università Cattolica del Sacro Cuore Updated

Spectroscopy From Duodenum

Chuo-ku : Novartis Investigative Site

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Fukuoka-shi : Kyushu University

Pancreatic Juice Diagnosis From Duodenum

Kashiwa : Novartis Investigative Site

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Koto : Novartis Investigative Site

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Sapporo-shi : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Takatsuki : Novartis Investigative Site

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Takatsuki-shi : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Anyang-si : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Cheonju-si : 1200.123.8203 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Daegu : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Goyang-si : National Cancer Center

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Incheon : 1200.123.8204 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

View More »

Jeollanam-do : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Jeonju-si : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Seongnam-si : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Seoul : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Seoul : 1200.123.8201 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Seoul : 1200.123.8205 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Seoul : 1200.123.8206 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Seoul : 1200.123.8202 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Songpa-gu : Asan Medical Center

Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)

Riga :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Amsterdam : Nederlands Kanker Instituut/Antonie van Leeuwenhoek Ziekenhuis

Optical Detection of Peripheral Nerve Bundles During Surgery

Rotterdam : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Oslo : 1200.123.4701 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Trondheim : 1200.123.4702 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Otwock : Novartis Investigative Site

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Arkhangelsk : State Budget Medical Institution of the Arkhangelsk Region

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Chelyabinsk : Chelyabinsk Regional Clinical Oncology Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Krasnodar : State Budget Medical Institution Clinical Oncology Center 1

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Omsk : Budget Medical Institution of the Omsk Region: Clinical Oncology Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Saint Petersburg : State Budget Medical Institution: Leningrad Regional Clinical Hospital

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

View More »

Tula : State Medical Institution: Tula Regional Oncology Center

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Singapore : 1200.123.6502 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Singapore : 1200.123.6501 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

A Coruna : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Barcelona : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Barcelona : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Barcelona : Novartis Investigative Site

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Barcelona : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Barcelona : ACROSS

XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

La Coruña : Centro Oncológico de Galícia

Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Madrid : Local Institution

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Madrid : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Madrid : 1200.123.3402 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Malaga : 1200.123.3404 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Oviedo : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Oviedo : 1200.123.3405 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Santander : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Santander : 1200.123.3403 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Sevilla : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Sevilla : 1200.123.3401 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Göteborg : 1200.123.4603 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Linköping : 1200.123.4602 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Lund : 1200.123.4601 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Stockholm : Dept. of Clinical Science, Intervention and Technology, Div. of surgery, Karolinska University Hospital, Huddinge

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Stockholm : 1200.123.4604 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Bern : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

St. Gallen : Novartis Investigative Site

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Taichung : 1200.123.8864 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Taichung : 1200.123.8865 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Tainan : 1200.123.8866 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Taipei : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Taipei : 1200.123.8861 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

View More »

Taipei : 1200.123.8862 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Tao-Yuan : 1200.123.8863 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Ankara :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Antalya :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Edirne :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Istanbul :

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Uzhhorod : Zakarpattia Regional Clinical Oncology Center Department of Chemotherapy

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Aberdeen : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Aberdeen : 1200.123.4401 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Birmingham : 1200.123.4406 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Cambridge : Cambridge University Hospitals NHS Foundation Trust

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

Cardiff : 1200.123.4402 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

View More »

Edinburgh : 1200.123.4404 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Glasgow : Novartis Investigative Site

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Guildford : 1200.123.4405 Boehringer Ingelheim Investigational Site

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Liverpool : Novartis Investigative Site

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

London : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Maidstone : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Manchester : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Sutton : Novartis Investigative Site Updated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Sutton : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Sutton : Novartis Investigative Site

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Wolverhampton : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients